Research ExplorerPublicationsFluorescence-guided bone resection in bisphosphonate-related...

Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study

Standard

Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study. / Pautke, Christoph; Bauer, Florian; Otto, Sven; Tischer, Thomas; Steiner, Timm; Weitz, Jochen; Kreutzer, Kilian; Hohlweg-Majert, Bettina; Wolff, Klaus-Dietrich; Hafner, Sigurd; Mast, Gerson; Ehrenfeld, Michael; Stürzenbaum, Stephen R; Kolk, Andreas.

In: J ORAL MAXIL SURG, Vol. 69, No. 1, 01.2011, p. 84-91.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Pautke, C, Bauer, F, Otto, S, Tischer, T, Steiner, T, Weitz, J, Kreutzer, K, Hohlweg-Majert, B, Wolff, K-D, Hafner, S, Mast, G, Ehrenfeld, M, Stürzenbaum, SR & Kolk, A 2011, 'Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study', J ORAL MAXIL SURG, vol. 69, no. 1, pp. 84-91. https://doi.org/10.1016/j.joms.2010.07.014

APA

Pautke, C., Bauer, F., Otto, S., Tischer, T., Steiner, T., Weitz, J., Kreutzer, K., Hohlweg-Majert, B., Wolff, K-D., Hafner, S., Mast, G., Ehrenfeld, M., Stürzenbaum, S. R., & Kolk, A. (2011). Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study. J ORAL MAXIL SURG, 69(1), 84-91. https://doi.org/10.1016/j.joms.2010.07.014

Vancouver

Pautke C, Bauer F, Otto S, Tischer T, Steiner T, Weitz J et al. Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study. J ORAL MAXIL SURG. 2011 Jan;69(1):84-91. https://doi.org/10.1016/j.joms.2010.07.014

Bibtex

@article{091077b821594864806397520feede19,
title = "Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study",
abstract = "PURPOSE: Surgical debridement is the therapy of choice in advanced stages of bisphosphonate-related osteonecrosis of the jaws (BRONJ). However, the therapy is currently only loosely standardized because no suitable imaging modalities exist. This study aims to redress this by exploring the suitability and reproducibility of applying a fluorescence-guided bone resection to patients with BRONJ.PATIENTS AND METHODS: This prospective pilot study comprised 15 patients with 20 BRONJ lesions (only stages II and III) with a history of intravenous bisphosphonate treatment for metastatic bone diseases. Before surgical treatment, each patient received a 10-day administration of doxycycline. Fluorescence-guided resection of necrotic bone was performed by means of a certified fluorescence lamp. Success of the procedure was proclaimed if mucosal closure was observed and symptoms were absent 4 weeks postoperatively.RESULTS: The 4-week postoperative follow-up identified a mucosal closure in 17 of 20 BRONJ lesions (85%). These patients were free of any symptoms. Failure as defined by mucosal dehiscence and exposed bone was observed in 3 of 20 BRONJ lesions (15%).CONCLUSION: The success rate of this surgical regimen of BRONJ was respectable, and thus fluorescence-guided bone resection can be considered an effective treatment for stage II and stage III BRONJ. Furthermore, the reproducibility of the technique offers an opportunity to standardize the surgical therapy. Further studies are called for that compare the fluorescence-guided bone resection with conventional surgical approaches, as well as surgical versus conservative treatment in the early stages (stages 0 and I) of BRONJ.",
keywords = "Adult, Aged, Bone Density Conservation Agents, Bone Neoplasms, Debridement, Diphosphonates, Doxycycline, Female, Fluorescence, Fluorescent Dyes, Follow-Up Studies, Humans, Imidazoles, Injections, Intravenous, Jaw Diseases, Male, Middle Aged, Osteonecrosis, Pilot Projects, Prospective Studies, Surgical Flaps, Surgical Wound Dehiscence, Treatment Outcome, Wound Healing",
author = "Christoph Pautke and Florian Bauer and Sven Otto and Thomas Tischer and Timm Steiner and Jochen Weitz and Kilian Kreutzer and Bettina Hohlweg-Majert and Klaus-Dietrich Wolff and Sigurd Hafner and Gerson Mast and Michael Ehrenfeld and St{\"u}rzenbaum, {Stephen R} and Andreas Kolk",
note = "Copyright {\textcopyright} 2011 American Association of Oral and Maxillofacial Surgeons. All rights reserved.",
year = "2011",
month = jan,
doi = "10.1016/j.joms.2010.07.014",
language = "English",
volume = "69",
pages = "84--91",
journal = "J ORAL MAXIL SURG",
issn = "0278-2391",
publisher = "W.B. Saunders Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study

AU - Pautke, Christoph

AU - Bauer, Florian

AU - Otto, Sven

AU - Tischer, Thomas

AU - Steiner, Timm

AU - Weitz, Jochen

AU - Kreutzer, Kilian

AU - Hohlweg-Majert, Bettina

AU - Wolff, Klaus-Dietrich

AU - Hafner, Sigurd

AU - Mast, Gerson

AU - Ehrenfeld, Michael

AU - Stürzenbaum, Stephen R

AU - Kolk, Andreas

N1 - Copyright © 2011 American Association of Oral and Maxillofacial Surgeons. All rights reserved.

PY - 2011/1

Y1 - 2011/1

N2 - PURPOSE: Surgical debridement is the therapy of choice in advanced stages of bisphosphonate-related osteonecrosis of the jaws (BRONJ). However, the therapy is currently only loosely standardized because no suitable imaging modalities exist. This study aims to redress this by exploring the suitability and reproducibility of applying a fluorescence-guided bone resection to patients with BRONJ.PATIENTS AND METHODS: This prospective pilot study comprised 15 patients with 20 BRONJ lesions (only stages II and III) with a history of intravenous bisphosphonate treatment for metastatic bone diseases. Before surgical treatment, each patient received a 10-day administration of doxycycline. Fluorescence-guided resection of necrotic bone was performed by means of a certified fluorescence lamp. Success of the procedure was proclaimed if mucosal closure was observed and symptoms were absent 4 weeks postoperatively.RESULTS: The 4-week postoperative follow-up identified a mucosal closure in 17 of 20 BRONJ lesions (85%). These patients were free of any symptoms. Failure as defined by mucosal dehiscence and exposed bone was observed in 3 of 20 BRONJ lesions (15%).CONCLUSION: The success rate of this surgical regimen of BRONJ was respectable, and thus fluorescence-guided bone resection can be considered an effective treatment for stage II and stage III BRONJ. Furthermore, the reproducibility of the technique offers an opportunity to standardize the surgical therapy. Further studies are called for that compare the fluorescence-guided bone resection with conventional surgical approaches, as well as surgical versus conservative treatment in the early stages (stages 0 and I) of BRONJ.

AB - PURPOSE: Surgical debridement is the therapy of choice in advanced stages of bisphosphonate-related osteonecrosis of the jaws (BRONJ). However, the therapy is currently only loosely standardized because no suitable imaging modalities exist. This study aims to redress this by exploring the suitability and reproducibility of applying a fluorescence-guided bone resection to patients with BRONJ.PATIENTS AND METHODS: This prospective pilot study comprised 15 patients with 20 BRONJ lesions (only stages II and III) with a history of intravenous bisphosphonate treatment for metastatic bone diseases. Before surgical treatment, each patient received a 10-day administration of doxycycline. Fluorescence-guided resection of necrotic bone was performed by means of a certified fluorescence lamp. Success of the procedure was proclaimed if mucosal closure was observed and symptoms were absent 4 weeks postoperatively.RESULTS: The 4-week postoperative follow-up identified a mucosal closure in 17 of 20 BRONJ lesions (85%). These patients were free of any symptoms. Failure as defined by mucosal dehiscence and exposed bone was observed in 3 of 20 BRONJ lesions (15%).CONCLUSION: The success rate of this surgical regimen of BRONJ was respectable, and thus fluorescence-guided bone resection can be considered an effective treatment for stage II and stage III BRONJ. Furthermore, the reproducibility of the technique offers an opportunity to standardize the surgical therapy. Further studies are called for that compare the fluorescence-guided bone resection with conventional surgical approaches, as well as surgical versus conservative treatment in the early stages (stages 0 and I) of BRONJ.

KW - Adult

KW - Aged

KW - Bone Density Conservation Agents

KW - Bone Neoplasms

KW - Debridement

KW - Diphosphonates

KW - Doxycycline

KW - Female

KW - Fluorescence

KW - Fluorescent Dyes

KW - Follow-Up Studies

KW - Humans

KW - Imidazoles

KW - Injections, Intravenous

KW - Jaw Diseases

KW - Male

KW - Middle Aged

KW - Osteonecrosis

KW - Pilot Projects

KW - Prospective Studies

KW - Surgical Flaps

KW - Surgical Wound Dehiscence

KW - Treatment Outcome

KW - Wound Healing

U2 - 10.1016/j.joms.2010.07.014

DO - 10.1016/j.joms.2010.07.014

M3 - SCORING: Journal article

C2 - 20971542

VL - 69

SP - 84

EP - 91

JO - J ORAL MAXIL SURG

JF - J ORAL MAXIL SURG

SN - 0278-2391

IS - 1

ER -